VANCOUVER, British Columbia, June 12, 2024 (GLOBE NEWSWIRE) -- Stallion Uranium Corp. (the "Company" or "Stallion") (TSX-V: STUD; OTCQB: STLNF; FSE: FE0) is pleased to announce the significant advancements and interpretations from the maiden drill program completed on the Appaloosa target, located on its 100% owned Coffer Project. Appaloosa is an advanced exploration target that is part of its broader portfolio of high-potential uranium projects held by Stallion in the prolific southwestern Athabasca Basin, ...

THE WOODLANDS, Texas, June 10, 2024 /PRNewswire/ -- Target Hospitality Corp. ("Target Hospitality", "Target" or the "Company") (NASDAQ: TH), one of North America's largest providers of vertically integrated modular accommodations and value-added hospitality services, today received notice that the U.S. government intends to terminate the existing South Texas Family Residential Center ("STFRC") services agreement with Target's migrant programming partner ("STFRC Partner"), effective in 60 days, or on or abou ...

Key TakeawaysNvidia shares finished slightly higher Monday after the chipmaker's 10-for-1 stock split, and several analysts raised their price targets for the stock. Barclays, Susquehanna, and TD Cowen analysts lifted their price objectives for Nvidia stock from their previous targets on a split-adjusted basis.The split-adjusted stock price could make ownership more accessible to a wider range of investors, with Morgan Stanley analysts highlighting that Nvidia stock is more affordable than Advanced Micro De ...

What should Nio (NYSE:NIO) stock be priced at? Bank of America has a $6 price target on the Chinese electric vehicle (EV) company, which it raised from $5.90.The price target change came after Nio reported its first-quarter earnings on May 6, revealing a 7.2% year-over-year revenue decline to $1.37 billion. BofA analyst Ming Hsun Lee noted that the decline was attributed to a lower average sales price (ASP). He rationalized that Nio wants to get rid of its 2023 models in preparation for new models.Revenue i ...

WILMETTE, Ill., June 10, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharmaceutical company focused on developing innovative treatments for cancer patients, is presenting today data from the preclinical development of its novel first-in-class lead radiopharma program MNPR-101-Zr at the 2024 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting in Toronto, Canada. SNMMI is the premier educational, scientific, and research event in the radiopharm ...

Realty Income is increasingly optimistic about its 2024 growth outlook.Realty Income (O -1.73%) is a terrific dividend stock. The real estate investment trust (REIT) has increased its dividend for 107 consecutive quarters. Its monthly payout currently yields nearly 6%, which is several times above the S&P 500's 1.3% dividend yield. The REIT's magnificent dividend should continue its steady rise. One factor driving that view is its growing optimism for securing new investments this year. The REIT recently ad ...

Fremont Provides Update on Urasar Exploration Program in Armenia: Seven Key Target Areas IdentifiedJune 06, 2024 7:30 AM EDT | Source: Fremont Gold Ltd.Vancouver, British Columbia--(Newsfile Corp. - June 6, 2024) - Fremont Gold Ltd. (TSXV: FRE) (FSE: FR20) (OTCQB: FRERF) ("Fremont" or the "Company") is pleased to provide an update on the 2024 exploration program at the Company's 100% owned Urasar Project ("Urasar" or the "Project") in northern Armenia.Dennis Moore, President and CEO of Fremont ...

UPPSALA, Sweden, June 06, 2024 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (Nasdaq: OLK) today announced the introduction of Olink Target 48 Immune Surveillance, a validated multiplexed protein assay panel that offers a detailed view of the immune system for in-depth monitoring of inflammation and immune response in clinical research. More Confidence, More Insights, Less Sample Biomarker selection for Olink Target 48 Immune Surveillance were designed to give researchers the most effective platform for detec ...

Collaboration will leverage Alphamab’s antibody drug conjugate (“ADC”) research and discovery platform and ArriVent’s global development and commercialization expertise Upfront and milestone payments to Alphamab worth up to $615.5 million for potential ADCs SUZHOU, China and NEWTOWN SQUARE, Pa., June 05, 2024 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc., (“ArriVent”) a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced that t ...

收入和利润 - 公司第一季度总收入为245亿美元，同比下降3.1%[39] - 调整后的每股收益为2.03美元，同比下降1.0%[37] - 销售总额为241.43亿美元，同比下降3.2%[39] - 其他收入为3.88亿美元，同比增加3.9%[39] - 营业利润为12.96亿美元，同比下降2.4%[39] - 毛利率为27.7%，同比增加1.4个百分点[46] - 销售及行政管理费用率为21.1%，同比增加1.3个百分点[47] 现金流量和财务状况 - 经营活动产生的现金流量为11亿美元，同比下降15.4%[36] - 公司现金及现金等价物余额为36亿美元，其中包括短期投资27亿美元[62] - 经营活动产生的现金流量为11亿美元，较去年同期减少2亿美元[63] - 投资活动所需现金减少至7亿美元，较去年同期减少9亿美元[65] - 公司拥有10亿美元364天和30亿美元无担保循环信贷额度，分别于2024年和2028年到期[70] 投资和债务 - 税后投资回报率为15.4%，同比增加4个百分点[38] - 公司长期债务评级为A2、A、A，商业票据评级为P-1、A-1、F1[69] 库存和运营 - 店铺数量从1956家增加到1963家[48] - 库存为117亿美元，较上季度和去年同期分别减少2亿美元和9亿美元[64] 股息和股票回购 - 公司支付的股息总额为508亿美元，每股股息为110美元，较去年同期增长19%[66] - 公司未在报告期内回购任何股票[67] 其他财务信息 - 公司预计新会计准则不会对财务报表产生重大影响[73] - 公司报告未提及市场风险管理有重大变化[76]